MedTrace Logo

Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus

NCT00608101 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2014-12-11

No results posted yet for this study

Summary

The purpose of this study is to determine what corticosteroid receptor (and the dose of) is responsible for cortisol inducing hypoglycemia associated autonomic dysfunction in Type 1 DM. Specifically, we aim to determine whether stimulating the type 1 corticosteroid receptor (via fludrocortisone), the type 2 corticosteroid receptor (via dexamethasone), or both causes hypoglycemia associated autonomic dysfunction in Type 1 DM.

Conditions

Interventions

DRUG

Fludrocortisone

Oral Fludrocortisone 0.2 mg x 2 prior to each experimental period on Day 1

DRUG

Dexamethasone

Oral Dexamethasone 0.75 mg x 2 administered prior to each experimental period on Day 1

Sponsors & Collaborators

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • Stephen N. Davis, MD · Vanderbilt University

Study Design

Allocation
RANDOMIZED
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2010-09-30
Completion
2010-09-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00608101 on ClinicalTrials.gov